Valuation: Madrigal Pharmaceuticals, Inc.

Market Cap 12.53B 11.02B 10.24B 9.41B 17.65B 1,213B 17.97B 122B 47.74B 592B 47.03B 46.01B 2,053B P/E 2026 *
-74.2x
P/E 2027 * 63.7x
Enterprise Value 12.01B 10.56B 9.81B 9.03B 16.93B 1,163B 17.23B 117B 45.78B 567B 45.1B 44.12B 1,968B EV / Sales 2026 *
8.02x
EV / Sales 2027 * 5.25x
Free-Float
94.11%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 59 2023-09-07
Director of Finance/CFO 62 2024-03-10
Chief Tech/Sci/R&D Officer 58 2025-04-20
Director TitleAgeSince
Director/Board Member 74 2016-06-30
Director/Board Member 68 2016-08-10
Director/Board Member 64 2019-06-26
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 12.4B
+1.23%+0.35%+51.62%+87.98% 55.27B
+5.09%+6.24%+63.15%+62.06% 54.15B
+0.25%+0.55%-19.67%-15.22% 23.22B
+0.72%-0.05%+3.84%+409.54% 23.11B
-0.76%+5.41%+30.59%-3.87% 20.33B
-0.37%+0.71%+31.36%-31.61% 17.91B
-0.96%+6.29%+33.32%+547.87% 15.76B
-2.54%-8.73%+164.11%+289.45% 15B
+1.22%-0.05%+22.58%+182.63% 13.82B
Average +0.41%+0.71%+42.32%+169.87% 26.51B
Weighted average by Cap. +1.24%+2.77%+43.54%+134.93%

Financials

2026 *2027 *
Net sales 1.5B 1.32B 1.22B 1.13B 2.11B 145B 2.15B 14.64B 5.71B 70.78B 5.63B 5.5B 246B 2.18B 1.92B 1.78B 1.64B 3.07B 211B 3.13B 21.3B 8.31B 103B 8.18B 8.01B 357B
Net income -210M -184M -171M -158M -295M -20.3B -301M -2.05B -799M -9.9B -787M -770M -34.35B 264M 232M 216M 198M 372M 25.55B 379M 2.58B 1.01B 12.46B 991M 969M 43.24B
Net Debt -515M -453M -421M -387M -726M -49.89B -739M -5.03B -1.96B -24.33B -1.93B -1.89B -84.42B -1.08B -946M -879M -809M -1.52B -104B -1.54B -10.51B -4.1B -50.83B -4.04B -3.95B -176B
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
915
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
543.35USD
Average target price
679.64USD
Spread / Average Target
+25.08%

Quarterly revenue - Rate of surprise